UnknownPhase 2

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

44 participantsStarted 2023-10-01

Plain-language summary

A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and PK of UB-621 in adults with recurrent genital HSV-2 infection

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. albumin\<3 g/dl
✕. ALP\>2.5\*ULN
✕. ALT\>2.5\*ULN
✕. AST\>2.5\*ULN
✕. Bilirubin\>1.5\*ULN
✕. CPK\>1.5\*ULN
✕. rGGT\>2.5\*ULN
✕. Hemoglobin: female\<11 g/dl; male\<12.5 g/dl

What they're measuring

Proportion of subjects with episodes before and after UB-621 treatment (self-comparison)

Timeframe: 16 weeks

Trial details

NCT IDNCT04714060

SponsorUBP Greater China (Shanghai) Co., Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-10-01

Contact for this trial

Linda Shih, DVM

+886 36684800 linda.shih@unitedbiopharma.com

View on ClinicalTrials.gov More Recurrent Genital Herpes trials